EN DE
Watch Amneal Pharmaceuticals, Inc. Class A Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Amneal Pharmaceuticals, Inc. Class A (AMRX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Amneal Pharmaceuticals, Inc. Class A stock $4.97, price $20.14, that is 75.3% below the price, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AP Amneal Pharmaceuticals, Inc. Class A logo Some data Nov 6, 2026

Amneal Pharmaceuticals, Inc. Class A

AMRX · US
Solid, but very expensive

Our calculation puts a fair price 75% below what the stock costs today.

Generates free cash flow
Profit last quarter +157% vs. a year ago.
Quality 57/100
Mixed Growth (revenue 5y +8.7 %/yr in USD)
Thin margins · 4.2% net margin (TTM)
Negative equity (buybacks among others)
Insiders sold $7.7M (6M)
Some data
Fair value $4.97 · Strongly overvalued
Trails peers (3/11)
Narrow moat 40/100 · thin data

Risks from the AI analysis

🚩Dependence on few large customers🚩Pricing pressure from named generics rivals🚩Overseas supply chain and tariff exposure
Watch Amneal Pharmaceuticals, Inc. Class A Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.51 $1.27 Fair Value $4.97 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $1.27 – $21.51 · fair‑value band $3.41 – $7.64 · the $20.14 price screens above the $4.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Amneal Pharmaceuticals, Inc. Class A Common Stock in your weekly email

Every Wednesday you see whether Amneal Pharmaceuticals, Inc. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.

Show moreShow less

The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.

The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease.

This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease.

The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.

This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.

It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies.

The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Stock analysis

Amneal Pharmaceuticals, Inc. Class A (AMRX) currently trades at $20.14, while our model-based Fair Value estimate is $4.97, 75% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $9.05 per share, and 0 of the 21 models we run sit above the $20.14 price.

Bear case: the Earnings-Based group reads lowest at $2.30, and 21 of the 21 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $3.41 (bear) to $7.64 (bull), the price of $20.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Amneal Pharmaceuticals, Inc. Class A Common Stock reported revenue of $3.0B in FY2025 versus $2.1B in FY2021, a compound +9.6%/yr. Reported net income was $72.1M in FY2025, compounding +61.4%/yr from FY2021.

Key figures

Market cap $6.6B Mid · P/E ratio 50.4 · P/S ratio 2.03 · EPS (TTM) $0.4000 · Net margin 4.2% · Return on equity 70.0% · Return on assets (EBIT) 5.2% (5-year average) · Operating margin 16.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 6% below its 52-week high and 77% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −75%, AMRX screens richer than that median.

Fair Value models

Bear $3.41 Fair Value $4.97 Bull $7.64
Price $20.14 · Downside -75.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3430 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $5.08 $10.87 $19.86 75
Growth DCF $5.01 $10.26 $18.02 74
EPV $1.60 $2.37 $3.02 72
All 21 models by family
DCF Models
FCF DCF $5.08 $10.87 $19.86 75
Owner Earnings $2.14 $5.98 $11.93 70
5Y Revenue Exit $3.37 $7.88 $13.83 68
5Y EBITDA Exit $5.89 $12.96 $21.68 71
5Y P/E Exit $1.47 $4.04 $6.82 66
10Y Revenue Exit $3.73 $8.02 $14.28 62
10Y EBITDA Exit $5.48 $11.50 $20.38 64
10Y P/E Exit $2.73 $5.39 $8.84 61
Earnings-Based
Graham-Dodd $1.41 $6.09 $8.32 64
Lynch FV $1.56 $2.23 $2.90 61
PEG = 1.0 $1.56 $2.23 $2.90 57
EPV $1.60 $2.37 $3.02 72
Multiples
P/E Multiple $3.41 $4.55 $5.69 63
P/S Multiple $2.64 $3.52 $4.40 57
EV/EBIT $4.80 $7.71 $10.62 63
EV/EBITDA $7.06 $10.72 $14.38 66
EV/Revenue $2.30 $4.97 $7.64 50
Growth DCF
Growth DCF $5.01 $10.26 $18.02 74
Rev-Margin DCF $3.37 $7.84 $13.50 68
Economic Profit
ROIC Compounder $2.11 $3.80 $5.90 68
Growth Earnings
Growth-Adj P/E $2.68 $3.82 $4.97 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 67
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 51
How calm the share price moves, does not count
Price momentum 89
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 93
Distance to the 52-week high, does not count
New shares 35
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $7.7M and none bought.

  • SaleJohn KielyDirector50,000 shares at $17.64$882,000Aug 13, 2026
  • SaleJason B. DalyEVP, Chief Legal Officer216,613 shares at $17.41$3.8MAug 12, 2026
  • SaleNikita ShahExecutive Vice President2× since Nov 12, 2025: 278,259 shares, avg. $14.86$4.1MAug 12, 2026
  • SaleDeborah M. AutorDirector34,819 shares at $12.94$450,558May 11, 2026
  • SaleTed C NarkDirector50,000 shares at $11.72$586,000Nov 17, 2025

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−8.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−8.2% vs −13.4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 14%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.5% a year for the price and +5.0% for the forecasts.
Forecast 2026 (sales)+6.0%
Forecast 2027 (sales)+9.2%
Projected 2028 (sales)+8.3%
Projected 2029 (sales)+7.4%
Projected 2030 (sales)+6.5%

AMRX screens overvalued: fair value 75% below the price. Compare with Merck KGaA →

Note from the team Oct 11, 2026
AI conclusion: The business draws strength from its in-house launch of a complex generic injectable expanding the portfolio, yet low margins combined with high debt and negative equity point to limited durable advantage.
Main risk: Sales are concentrated with wholesalers and retailers such as Cencora, McKesson, Cardinal Health and CVS Health, so their loss or reduced orders could materially reduce results with no long-term agreements in place.
Bull case: By successfully scaling its biosimilars pipeline and complex generics through the Kashiv acquisition the company could diversify away from concentrated customers and offset pricing pressure with higher-margin products.
Bear case: If customer concentration leads to lost orders and rivals continue to erode prices and exclusivity the generics portfolio could face sustained margin compression and slower overall revenue growth.
Amneal recently gained FDA approval and launched a generic version of lanreotide, a long-acting injectable tied to nearly a billion dollars in prior US annual brand sales. The move adds to its complex generics portfolio via in-house production. Our models currently see the stock as overvalued, so will this product deliver lasting revenue gains amid generic pressures, or will the rest of the portfolio constrain results?
Join the discussion →

Compare Amneal Pharmaceuticals, Inc. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside −75.3% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 3.5% · Below median
Net margin (12 months) 7.4% · Below median
Operating margin (12 months) 16.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 10.0% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 50.4× · Priciest 25%
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 3.67× · Pricier than median
Price / free cash flow (fiscal year) 43.5× · Priciest 25%
EV/EBITDA 21.3× · Pricier than median
PEG 1.92× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)50 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs AMRX
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs AMRX
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs AMRX
Haleon plc HLN $9.14 $8.61 −6% vs AMRX
Merck KGaA MRK €148.75 €109.18 −27% vs AMRX
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs AMRX
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs AMRX
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs AMRX
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs AMRX
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs AMRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amneal Pharmaceuticals, Inc. Class A Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Amneal Pharmaceuticals, Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/AMRX

Frequently asked questions

Is Amneal Pharmaceuticals, Inc. Class A (AMRX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $4.97 versus a price of $20.14, about 75% lower (overvalued).
What is the fair value of AMRX?
Our model-based fair value for Amneal Pharmaceuticals, Inc. Class A is $4.97 (as of Nov 6, 2026), built from audited fundamentals. The current price: $20.14.
What is the quality score of AMRX?
Amneal Pharmaceuticals, Inc. Class A has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Our model-based price target is the fair value of $4.97 (as of Nov 6, 2026) from 21 valuation models. Cautious scenario $3.41, optimistic scenario $7.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Amneal Pharmaceuticals, Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $4.97, about 75% lower versus a price of $20.14 (overvalued). Cautious scenario $3.41, optimistic scenario $7.64. The calculation is refreshed regularly with new filings.
What is the revenue of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Amneal Pharmaceuticals, Inc. Class A reported trailing-twelve-month revenue of about $3.2B (latest available figure, as of Nov 6, 2026).
What growth is priced into Amneal Pharmaceuticals, Inc. Class A (AMRX)?
For today's price to be fair in a discounted-cash-flow model, Amneal Pharmaceuticals, Inc. Class A would have to grow free cash flow by +20.3 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.7 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of AMRX use?
Our models discount Amneal Pharmaceuticals, Inc. Class A at 10.2 %: a base by market capitalisation (mid), damped by beta 1.21, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Amneal Pharmaceuticals, Inc. Class A that is +20.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Amneal Pharmaceuticals, Inc. Class A (AMRX) delivered so far?
Over the past 5 years revenue at Amneal Pharmaceuticals, Inc. Class A grew +8.7 % a year. The price currently implies free-cash-flow growth of +20.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Amneal Pharmaceuticals, Inc. Class A (AMRX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Amneal Pharmaceuticals, Inc. Class A (+20.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The free-cash-flow yield on the price is 4.08 %: that much free cash flow Amneal Pharmaceuticals, Inc. Class A produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amneal Pharmaceuticals, Inc. Class A it is $4.97 per share (as of Nov 6, 2026), against a price of $20.14. It is the blended result of 21 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Amneal Pharmaceuticals, Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, AMRX trades above its calculated fair value: price $20.14, fair value $4.97, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMRX?
No. The price is what the market pays today ($20.14); the fair value is what the company's own numbers justify ($4.97). For Amneal Pharmaceuticals, Inc. Class A the two are $15.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amneal Pharmaceuticals, Inc. Class A Common Stock worth?
The market values Amneal Pharmaceuticals, Inc. Class A at about $6.6B (market capitalisation, as of Nov 6, 2026). Per share that is $20.14; our models calculate a fair value of $4.97 per share.
What do the bullish and bearish scenarios say about AMRX?
Our models span a range for Amneal Pharmaceuticals, Inc. Class A: cautious scenario $3.41, base $4.97, optimistic $7.64 per share (as of Nov 6, 2026, price $20.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AMRX?
Amneal Pharmaceuticals, Inc. Class A trades at a price-to-earnings ratio of 50.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.97 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2016 to 2025), reported earnings: 12.1. Other multiples: PEG 1.9, P/S 3.7, EV/EBITDA 21.3.
What is the PEG ratio of AMRX?
The PEG ratio of Amneal Pharmaceuticals, Inc. Class A is 1.92 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Balance-sheet figures for Amneal Pharmaceuticals, Inc. Class A (as of Nov 6, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is AMRX from its 52-week high?
Amneal Pharmaceuticals, Inc. Class A trades at $20.14, about 6% below its 52-week high of $21.51 and 77% above the low of $11.37 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.97 is for.
Which stocks are comparable to Amneal Pharmaceuticals, Inc. Class A Common Stock?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amneal Pharmaceuticals, Inc. Class A Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $20.14, calculated fair value $4.97 (−75%), Quality Score 57/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMRX calculated?
We run Amneal Pharmaceuticals, Inc. Class A through 21 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $4.97 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Amneal Pharmaceuticals, Inc. Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The closing price on Nov 6, 2026 was $20.14. Our model-based fair value is $4.97, about 75% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amneal Pharmaceuticals, Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($7.64). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($3.41 to $7.64) leaves room in how you read the outcome.

Key figures of Amneal Pharmaceuticals, Inc. Class A

How large is the market capitalisation of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The market capitalisation of Amneal Pharmaceuticals, Inc. Class A is $6.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The price-to-sales ratio of Amneal Pharmaceuticals, Inc. Class A is 2.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Earnings per share at Amneal Pharmaceuticals, Inc. Class A are $0.4000 (price ÷ EPS = P/E 50.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The net margin of Amneal Pharmaceuticals, Inc. Class A is 4.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The return on equity (ROE) of Amneal Pharmaceuticals, Inc. Class A is 70.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
On an EBIT basis the return on assets of Amneal Pharmaceuticals, Inc. Class A is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amneal Pharmaceuticals, Inc. Class A (AMRX)?
The operating margin of Amneal Pharmaceuticals, Inc. Class A is 16.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Revenue at Amneal Pharmaceuticals, Inc. Class A is growing +10.0% versus a year earlier (3y avg +10.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amneal Pharmaceuticals, Inc. Class A (AMRX)?
Earnings per share at Amneal Pharmaceuticals, Inc. Class A are growing +157% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Amneal Pharmaceuticals, Inc. Class A (AMRX) carry?
The net debt of Amneal Pharmaceuticals, Inc. Class A is $2.4B (fiscal year 2025, ≈ 9.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Amneal Pharmaceuticals, Inc. Class A Common Stock in the live analysis

One click puts Amneal Pharmaceuticals, Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.